Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

Preferred Stock Conversion calculation, Series H

Number of Series H Preferred Stock outstanding		8
Multiplied by the stated value	$	154
Equals the gross stated value	$	1,232
Divided by the conversion price	$	36.96
Equals the convertible shares of common stock		33
Multiplied by the fair market value of common stock at March 31, 2020	$	0.45
Equals the payment	$	15

Preferred Stock Conversion calculation, Series H-3

Number of Series H-3 Preferred Stock outstanding		2,189
Multiplied by the stated value	$	138
Equals the gross stated value	$	302,082
Divided by the conversion price	$	33.12
Equals the convertible shares of common stock		9,121
Multiplied by the fair market value of common stock at March 31, 2020	$	0.45
Equals the payment	$	4,104

Preferred Stock Conversion calculation, Series H-4

Number of Series H-4 Preferred Stock outstanding		5,028
Multiplied by the stated value	$	235.50
Equals the gross stated value	$	1,184,094
Divided by the conversion price	$	2.826
Equals the convertible shares of common stock		419,000
Multiplied by the fair market value of common stock at March 31, 2020	$	0.45
Equals the payment	$	188,550

Preferred Stock Conversion calculation, Series H-6

Number of Series H-6 Preferred Stock outstanding		29,822
Multiplied by the stated value	$	72.00
Equals the gross stated value	$	2,147,184
Divided by the conversion price	$	0.72
Equals the convertible shares of common stock		2,982,200
Multiplied by the fair market value of common stock at March 31, 2020	$	0.45
Equals the payment	$	1,341,990

Schedule of share-based compensation, stock options, activity

	Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2019		380,396		$	14.43		6.84		-
Expired		(73,194	)		35.53		-
Outstanding at March 31, 2020		307,202		$	9.39		8.20		-

Schedule of share-based compensation

	Three Months ended March 31,
	2020		2019
Research and development		3,758		3,717
Selling, general and administrative		45,586		484,240
Total $		49,344	$	487,957

Schedule of common stock warrant activity

	Shares Underlying Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2019		4,300,560	$	1.77		5.06		-
Granted		-		-		-		-
Exercised/Forfeited		-		-		-		-
Outstanding at March 31, 2020		4,300,560	$	1.77		4.81		-